AbbVie (ABBV) Stock Forecast & Price Target

$202.02 +1.15 (+0.57%)

Closing price 02/21/2025 03:59 PM Eastern

Extended Trading

$201.53 -0.50 (-0.25%)

As of 02/21/2025 07:59 PM Eastern

AbbVie - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 24 Analyst Ratings

Sell
0

Hold
5

Buy
19

Based on 24 Wall Street analysts who have issued ratings for AbbVie in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 24 analysts, 5 have given a hold rating, 17 have given a buy rating, and 2 have given a strong buy rating for ABBV.

Consensus Price Target

$208.35
3.13% Upside

According to the 24 analysts' twelve-month price targets for AbbVie, the average price target is $208.35. The highest price target for ABBV is $239.00, while the lowest price target for ABBV is $180.00. The average price target represents a forecasted upside of 3.13% from the current price of $202.03.

Get the Latest News and Ratings for ABBV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for AbbVie and its competitors.

ABBV Analyst Ratings Over Time

Type	Current Forecast 2/23/24 to 2/22/25	1 Month Ago 1/24/24 to 1/23/25	3 Months Ago 11/25/23 to 11/24/24	1 Year Ago 2/23/23 to 2/23/24
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	2 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	17 Buy rating(s)	17 Buy rating(s)	18 Buy rating(s)	10 Buy rating(s)
Hold	5 Hold rating(s)	5 Hold rating(s)	3 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$208.35	$205.50	$203.50	$175.36
Forecasted Upside	3.13% Upside	20.59% Upside	15.00% Upside	-1.55% Downside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

ABBV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ABBV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

AbbVie Stock vs. The Competition

Type	AbbVie	Medical Companies	S&P 500
Consensus Rating Score	2.88	2.82	2.53
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	3.13% Upside	29,427.70% Upside	14.37% Upside
News Sentiment Rating	Positive News See Recent ABBV News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
2/3/2025	Citigroup 3 of 5 stars	P. Verdult Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$205.00 ➝ $215.00	+13.03%
2/3/2025	Truist Financial 2 of 5 stars	Srikripa Devarakonda Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$211.00 ➝ $217.00	+14.50%
2/3/2025	UBS Group 4 of 5 stars	Navin Jacob Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$181.00 ➝ $190.00	+0.71%
2/3/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Mohit Bansal Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$195.00 ➝ $210.00	+11.23%
2/3/2025	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Terence Flynn Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$224.00 ➝ $239.00	+26.86%
2/3/2025	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Gary Nachman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$218.00 ➝ $220.00	+19.63%
2/3/2025	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Vamil Divan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$212.00 ➝ $214.00	+16.37%
2/3/2025	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Evan David Seigerman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$208.00 ➝ $215.00	+16.91%
12/17/2024	Piper Sandler Companies Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$220.00	+25.13%
12/10/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral	$191.00	+8.14%
Get the Latest News and Ratings for ABBV and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter.
12/5/2024	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	N. Nakagiri Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
12/5/2024	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Neutral	$180.00	+1.95%
11/22/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
11/22/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$206.00	+19.64%
11/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Hammond Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$205.00	+20.85%
11/13/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$210.00 ➝ $200.00	+16.74%
11/4/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Toung Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy
10/17/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Breen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$203.00	+6.58%
10/7/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$200.00 ➝ $212.00	+9.75%
10/7/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$195.00 ➝ $225.00	+16.22%
8/30/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Phipps Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/5/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$200.00 ➝ $200.00	+8.40%
6/5/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$185.00	+14.08%
12/11/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$173.00	+15.89%
11/9/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold	$150.00	+5.60%
7/12/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$170.00 ➝ $160.00	+18.02%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 04:28 AM ET.

Should I Buy AbbVie Stock? ABBV Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, February 17, 2025. Please send any questions or comments about these AbbVie pros and cons to contact@marketbeat.com.

AbbVie
Bull Case

Here are some ways that investors could benefit from investing in AbbVie:

AbbVie offers a strong dividend yield of 3.40%, providing a reliable income stream for investors. The company has announced a dividend of $1.64, which reflects its commitment to returning value to shareholders.
The stock is currently trading at $193.00, which is near its 1-year high of $207.32, indicating strong market performance and investor confidence.
AbbVie has a diverse portfolio of innovative products, including the latest treatments like Rinvoq and Skyrizi, which are gaining traction in the market for autoimmune diseases and psoriasis, respectively.
Institutional ownership stands at 70.23%, suggesting that many professional investors have confidence in AbbVie’s long-term prospects, which can be a positive indicator for retail investors.
The company has a robust pipeline of drugs in development, which could lead to future growth and revenue, enhancing its market position in the pharmaceutical industry.

AbbVie
Bear Case

Investors should be bearish about investing in AbbVie for these reasons:

AbbVie has a high dividend payout ratio of 273.33%, which may raise concerns about the sustainability of its dividend payments in the long term, especially if earnings do not grow as expected.
The stock has experienced volatility, with a 1-year low of $153.58, indicating potential risks associated with price fluctuations that could affect investor returns.
Recent insider selling, including a senior vice president selling 1,800 shares, may signal a lack of confidence among company executives regarding future performance.
AbbVie faces significant competition in the pharmaceutical market, which could impact its market share and profitability, particularly for its key products.
Regulatory challenges and the need for ongoing research and development investments could strain financial resources, potentially affecting overall financial health.

ABBV Forecast - Frequently Asked Questions

: According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for AbbVie is $208.35, with a high forecast of $239.00 and a low forecast of $180.00.
: 24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last twelve months. There are currently 5 hold ratings, 17 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ABBV shares.
: According to analysts, AbbVie's stock has a predicted upside of 3.13% based on their 12-month stock forecasts.
: Over the previous 90 days, AbbVie's stock had 2 downgrades by analysts.
: AbbVie has been rated by research analysts at Bank of America, BMO Capital Markets, Citigroup, Daiwa America, Daiwa Capital Markets, Guggenheim, Morgan Stanley, Piper Sandler, Piper Sandler Companies, Raymond James, Truist Financial, UBS Group, and Wells Fargo & Company in the past 90 days.
: Analysts like AbbVie more than other "medical" companies. The consensus rating score for AbbVie is 2.88 while the average consensus rating score for "medical" companies is 2.82. Learn more on how ABBV compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:ABBV) was last updated on 2/22/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AbbVie (ABBV) Stock Forecast & Price Target